Skip to main content

We’ve updated our Terms & Conditions and Privacy Policy. By using this site, you agree to these terms.

Hospital reaches milestone in less-invasive heart treatment

DANVILLE, Pa. – Geisinger Medical Center’s (GMC) structural heart disease team recently performed its 1000th transcatheter aortic valve replacement (TAVR) at the hospital. 

TAVR is a less-invasive approach to treating diseased and narrowed aortic valves (aortic stenosis). Physicians can replace a diseased valve without performing open-heart surgery. Instead, they insert a small, thin tube (catheter) into an artery in the groin and feed a new, collapsed valve to the heart where it is deployed to regulate blood flow. 

Unlike traditional heart valve surgery, known as surgical aortic valve replacement (SAVR), TAVR requires only a small puncture and allows for quicker recovery and shorter hospital stays. 

“We developed the first program in the region to offer TAVR, and we’ve been performing the procedure longer than any other health system in northeastern and central Pennsylvania,” said Shikhar Agarwal, M.D., interventional cardiologist at GMC. “Performing 1,000 procedures is an achievement that displays our deep experience and specialized expertise. We are making better health easier by treating a wide range of patients with aortic stenosis and getting them back to their active lifestyles quickly.”

Geisinger began offering TAVR in 2011 when the procedure was approved for patients in need of valve replacement but at high risk for complication with SAVR. Since then, the treatment has been approved for patients at moderate and low risk, and the TAVR program has grown to care for patients at Geisinger Wyoming Valley Medical Center in Wilkes-Barre and Geisinger Community Medical Center in Scranton. 

Patients with valve disease are evaluated by Geisinger’s heart valve team to determine the best therapy for each patient. For many patients, including those who have more than one damaged valve or coronary artery disease, SAVR is still the most appropriate and safest treatment. But TAVR is now a proven option, producing positive health outcomes in patients of all risk levels with the added benefits of faster healing and discharge processes. 

“Reaching this milestone is a testament to the proficiency our team has built over the last 11 years and the trust we’ve earned in the communities we serve,” said Dr. Agarwal. “I’m grateful for the hard work and compassionate care of every member of the structural heart disease team, past and present, whose dedication and service to our patients has led this program to where it is today.”
 

About Geisinger
Geisinger is among the nation’s leading providers of value-based care, serving 1.2 million people in urban and rural communities across Pennsylvania. Founded in 1915 by philanthropist Abigail Geisinger, the non-profit system generates $10 billion in annual revenues across 134 care sites - including 10 hospital campuses, and Geisinger Health Plan, with 600,000 members in commercial and government plans. The Geisinger College of Health Sciences educates more than 5,000 medical professionals annually and conducts more than 1,400 clinical research studies. With 26,000 employees, including 1,600 employed physicians, Geisinger is among Pennsylvania’s largest employers with an estimated economic impact of $14 billion to the state’s economy. On March 31, 2024, Geisinger became the first member of Risant Health, a new nonprofit charitable organization created to expand and accelerate value-based care across the country.  Learn more at geisinger.org or connect with us on Facebook, Instagram, LinkedIn and X.

Geisinger Logo

For media inquires:

R. Matthew Mattei
Senior Communications Specialist

570-808-3971
rmmattei1@geisinger.edu
Content from General Links with modal content